La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sintx Technologies Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Eric Olson

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	9.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Eric Olson (61 yo)

less than a year

Mandato

US$2,968,822

Compensazione

Mr. Eric K. Olson was Director and President of Amedica Spine of Sintx Technologies, Inc. Mr. Eric K. Olson is President, CEO & Director of Sintx Technologies, Inc. from 2024. Mr. Eric K. Olson serves as t...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Eric Olson	President	less than a year	US$2.97m	Nessun dato
David Truetzel	Independent Director	14yrs	US$124.21k	0% $ 0
Erik Stookey	Independent Director	9.9yrs	US$43.43k	0% $ 0
B. Bal	Chairman of the Board	12.6yrs	US$536.95k	0.00013% $ 3.3
Jeffrey White	Independent Director	10.7yrs	US$43.43k	Nessun dato
Mark Froimson	Independent Director	5.6yrs	US$43.18k	0% $ 0
Giuseppe Pezzotti	Member of Scientific Advisory Board	9yrs	Nessun dato	Nessun dato

9.9yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0A8S sono considerati esperti (durata media dell'incarico 9.9 anni).

Sintx Technologies Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Sintx Technologies, Inc. Announces Appointment of Eric K. Olson as Chief Executive Officer

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

Insufficient new directors

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Insufficient new directors

Recent updates

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $3.114779 million.

Second quarter 2024 earnings released: US$3.49 loss per share (vs US$122 loss in 2Q 2023)

Sintx Technologies, Inc. Announces Appointment of Eric K. Olson as Chief Executive Officer

Sintx Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.115475 million.

Sintx Technologies Regains Compliance with Nasdaq Bid Price Requirement

Sintx Technologies Declares 1-for-200 Reverse Stock Split Effective May 28, 2024 to Bring it into Compliance with the Minimum Bid Price Requirements for Maintaining the Listing on the Nasdaq Capital Market

New major risk - Financial position

First quarter 2024 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2023)

Sintx Technologies Receives New Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Sintx Technologies, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$2.22 loss per share (vs US$54.67 loss in FY 2022)

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $1.030519 million.

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$11.02 loss in 3Q 2022)

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

SINTX Technologies Receives a Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Sintx Technologies, Inc. Receives Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$10.16 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$11.51 loss in 1Q 2022)

Full year 2022 earnings released: US$54.67 loss per share (vs US$35.54 loss in FY 2021)

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Insufficient new directors

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sintx Technologies Receives Notice from the Listing Qualifications Staff of Nasdaq

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.095 loss in 3Q 2021)

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $4.7 million.

Sintx Technologies, Inc. Announces New Antibacterial Biomedical Patents and Expansion of Intellectual Property Portfolio

National Institutes of Health Announces Grant to Sintx Technologies for Development of 3D Printed Antimicrobial Trauma Device

Insufficient new directors

Insufficient new directors

Oxford Performance Materials and SINTX Technologies Collaboration Yields Major Breakthrough in Orthopedic & Dental Coatings

No longer forecast to breakeven

Second quarter 2022 earnings released: US$0.10 loss per share (vs US$0.089 loss in 2Q 2021)

Insufficient new directors

Sintx Technologies, Inc. (NasdaqCM:SINT) acquired Technology Assessment And Transfer, Inc. for 0.76 million.

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

Full year 2021 earnings released: US$0.35 loss per share (vs US$1.01 loss in FY 2020)

No longer forecast to breakeven

Insufficient new directors

SINTX Technologies, Inc. Announces New Results on the Development of Manufacturing Technologies to Produce Fabrics Impregnated with SINTX Silicon Nitride, and the Antipathogenic Testing of These Fabrics

SINTX Technologies Receives A Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.095 loss per share (vs US$0.11 loss in 3Q 2020)

Sintx Technologies, Inc. Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY

First quarter 2021 earnings released: US$0.11 loss per share (vs US$1.35 loss in 1Q 2020)

SINTX Technologies Announces New Product Brand, FleX SN, For Antipathogenic and Biomedical Applications

SINTX Technologies Files Multiple New U.S. and International Patent Applications

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Membri del Consiglio di amministrazione

Durata media

Età media